PTEN hamartoma of soft tissue (PHOST) that may contain fast flow vascular anomalies (FFVA). [6] [7] [8] Patients with PHTS need life-long support and management for recurrent symptoms and cancer screening. 3 The use of oral sirolimus, 9 surgical excision of PHOST, 10 and embolization of FFVA 11, 12 have been reported, but a comprehensive management approach with the role of each treatment modality has not been outlined. The purpose of this study is to report the temporal evolution and management of FFVA in patients with PHTS using a multidisciplinary approach.
Materials and Methods
An institutional review board approved, retrospective review of 22 patients (M:F ¼ 9:13) in the age range of 1 to 18 (median 9) years diagnosed with PHTS (on the basis of heterozygous germline mutation) at a tertiary care pediatric hospital between October 2002 and August 2017 was performed, and 4 patients with FFVA were identified. Patient demographic information, clinical features of PHTS, and location of PHOST are outlined in ►Table 2. Imaging studies Operational diagnosis in an individual (either of the following) (1) Three or more major criteria, but one must include macrocephaly, Lhermitte-Duclos disease, or gastrointestinal hamartomas; or (2) Two major and three minor criteria.
Operational diagnosis in a family where one individual meets revised PHTS clinical diagnostic criteria or has a PTEN mutation (1) Any two major criteria with or without minor criteria; or (2) One major and two minor criteria; or (3) Three minor criteria.
Abbreviation: PHTS, PTEN hamartoma tumor syndrome; PTEN, phosphatase and tensin homolog. Additionally all three males had penile lentigines/freckling. The association of macrocephaly, vascular anomalies, and macular pigmentation of the glans penis constituted two major and one minor criteria for PHTS. 4, 5 The female patient had macrocephaly, vascular anomalies, and mild intellectual disability (one major and two minor criteria). Based on these clinical criteria, genetic testing was performed, and the diagnosis of PHTS was confirmed. In three patients, the PTEN hamartoma and FFVA involved more than one anatomical body part, but were contiguous (►Fig. 1). One patient (patient 1) developed a new noncontiguous (left chest wall) hamartoma and FFVA 7 years after the diagnosis of the initial lesion (right foot and calf). During follow-up, ultrasound and MRI performed for evaluation of recurrent pain demonstrated progressive increase in the size of the PTEN hamartoma (►Fig. 2a) and development of new FFVA within existing hamartoma in three-fourth patients (►Fig. 2b). In addition to previously described angiographic features such as arteriovenous, arteriolovenous, and arteriolovenulous anomalies, segmental-beaded arterial ectasia of the proximal peroneal artery and sidetoside fistula with the adjacent peroneal vein was seen in 
Medical Management
Medical management included oral sirolimus (mammalian target of rapamycin [mTOR] inhibitor) that was recommended to all four patients. The medication was started at a dose of 0.8 mg/m 2 /dose twice daily 3 months to 6 years after the initial presentation. Serum levels of sirolimus were monitored, and dose was titrated to target trough levels of 7 to 10 ng/ml. There were periods when families decided to hold the medication due to various reasons, but all patients had been on/off sirolimus during the study (►Fig. 3). During sirolimus therapy, patients were advised to respect a low-fat diet, and basic hematologic and metabolic screening (complete blood count, electrolytes, renal and hepatic function tests, and serum triglyceride levels) were monitored monthly. In addition, live vaccines were contraindicated, and Pneumocystis jiroveci pneumonia prophylaxis was administered. Patients underwent regular clinical follow-up to monitor response to treatment. Pain secondary to hamartoma responded to sirolimus, but recurred upon the discontinuation of the medication. There was no correlation between serum sirolimus levels and frequency or timing of recurrence of hamartoma or FFVA (►Fig. 3). Complications related to sirolimus were as follows: (1) oral mucositis in all patients managed with local treatment, (2) elevated triglycerides managed with low-fat diet and improved control of serum sirolimus level, and (3) noncompliance with daily dosing resulting in variable serum levels (►Fig. 3). All patients were enrolled in a regular physical therapy program that focused on strengthening and range of motion of the involved muscles particularly during the recovery period after IR procedures.
Surgical Management
Surgical excision was performed in one patient (patient 3) with PTEN hamartoma in the hand and forearm. This was helpful in short-term improvement in range of motion of the hand, but was followed by recurrent symptomatic hamartoma and FFVA in 3 months. 
Interventional Radiology Management
The following two types of IR treatments were performed based on imaging findings and the character of the patient's pain: (1) staged embolization of FFVA using transarterial, percutaneous intranidal, percutaneous, and retrograde transvenous approaches and (2) percutaneous interstitial sclerosant injection of PTEN hamartoma. Patients presenting with pain at and/or distal to the location of FFVA that was worse with activity and relieved with rest were managed with staged embolization of FFVA since this type of pain was typical of steal phenomenon due to arteriovenous shunting. Patients with constant pain unrelated to activity at the site of PTEN hamartoma that occurred despite complete/near complete embolization of FFVA were thought to have pain due to tumor proliferation and hypertrophic nerves and were managed with intratumoral injection of sclerosant.
A variety of embolic and sclerosing agents such as Dehydrated Alcohol (Akorn, Lake forest, IL), Bleomycin (APP Pharmaceuticals, Schaumburg, IL), 3% for a total of 4 to 24 procedures per patient. The number of embolization procedures, approach, agent, and complications are outlined in ►Table 3. Pain related to FFVA responded well to embolization of arteriovenous shunts. However, pain secondary to the PTEN hamartoma responded poorly to percutaneous sclerosant injection of PTEN hamartoma. One patient (patient 1) had migration of sclerosant into digital arteries during percutaneous intratumoral injection of 3% sodium tetradecyl sulfate for management of recurrent foot pain. This led to ischemic necrosis and autoamputation of fourth and fifth toes. During transarterial injection of glue in a left chest wall vascular anomaly in the same patient, there was migration of glue into the proximal subclavian vein resulting in venous stenosis and worsening venous hypertension of the left upper extremity. This was subsequently managed with angioplasty and stent placement.
Discussion
PTEN hamartoma tumor syndrome was recently described to encompass syndromes with overlapping phenotypes that share a germline mutation in the PTEN gene.
1-3 Kurek et al
introduced the term PTEN hamartoma of soft tissue for a unique finding of infiltrative intramuscular lesions containing fat, hypertrophic nerves with increased proliferation of periaxonal spindled cells, and serpiginous vessels. 6 The authors noted that patients with PHOST presented with pain and swelling before the age of 15 years with intramuscular lesions most commonly in the lower extremity. Similarly, three-fourth patients in the present study had lower extremity intramuscular lesions that presented with pain and swelling in early childhood. One patient had the same clinical presentation, but affecting the upper extremity. The findings of heterogeneity, infiltrative nature, structural disorganization, and excess fat described by Kurek et al were also seen in the present study. In addition, the present study demonstrates temporal evolution of these lesions: (1) Tan et al divided vascular anomalies into arteriovenous, arteriolovenous, and arteriolovenulous and described disproportionate dilatation of the proximal draining veins as a unique feature of FFVA in patients with PHTS. 8 In addition to these features, one patient in the present study developed segmental-beaded arterial ectasia and large side-to-side fistula with the adjacent deep vein during follow-up. This resulted in large volume arteriovenous shunting with steal phenomenon that responded to transvenous occlusion of the arteriovenous communication.
Management of FFVA in patients with PTEN hamartoma is challenging and requires a multidisciplinary approach. Since patients present with recurrent pain and swelling, addressing the chronic pain is a critical component of their care. Understanding the mechanism of pain is crucial as therapy could target the trigger without having a universal recipe. Pain may be related to steal phenomenon from arteriovenous shunting (ischemic pain) and responds well to embolization. It may also be caused by the actively proliferating hamartoma secondary to presence of hypertrophic nerves or to mass effect on the surrounding tissues. Other benign tumors that are a hallmark of PTEN hamartoma tumor syndrome-trichilemmomas and oral papillomas-are not routinely associated with pain.
1,2
PTEN is a natural inhibitor of the mTOR pathway, and when the gene is mutated (inactivated) or deleted, the pathway is overly active inducing pathogenic proliferation usually of mesenchymal elements. Sirolimus is an mTOR inhibitor that if administered daily regains some control over the downstream elements with resulting antiproliferative and antiangiogenic properties. As described in previous studies, PTEN hamartomas in the present study became softer and less painful and showed improved function of the affected region during administration of sirolimus. 9 It did not however prevent increase in the size of the hamartoma or development of new FEVA. The medication had few side effects and was generally well tolerated during long-term administration. Introducing medical therapy with sirolimus improved pain and, thus, the quality of life in all patients in the present study. There was however recurrence of pain whenever the medication was discontinued, perhaps due pathologic proliferation from reactivation of the mTOR pathway. It is known that sirolimus does not have cytotoxic effect and is unable to reduce the size of an already formed arteriovenous malformation that is best addressed with IR procedures. The goal of IR procedures is to obliterate abnormal arteriovenous communications, to improve perfusion to distal tissues, and to alleviate pain from steal phenomenon. The approach to treatment has to be tailored according to the angioarchitecture and ability to access the arteriovenous communications. The standard approach to management of congenital arteriovenous malformations is useful and applicable to FFVA in patients with PHTS. 15, 16 In the present study, the complexity of angioarchitecture required the use of transarterial, transvenous, and direct percutaneous approaches using several embolic agents and sclerosants during each procedure. 16 The largest and most distal arteriovenous communications were occluded first to improve distal perfusion and to alleviate pain from steal phenomenon. The dilated ectatic proximal draining veins of FFVA served as a useful target for retrograde 11 or percutaneous transvenous embolization that was performed in three patients resulting in complete resolution of pain. In addition to occlusion of FFVA, direct percutaneous interstitial injection of sclerosant into the PTEN hamartoma was used in this study. Although this was technically successful during two procedures, the clinical success in terms of pain response was limited, and there was inadvertent migration of sclerosant into the digital arteries during a third procedure. Since PTEN hamartoma contains multiple abnormal vessels, this approach should be used with caution. Occlusion of larger arteriovenous communications had the best clinical response, but there was always recurrence of pain requiring repeated IR procedures alongside medical management. Due to the intramuscular location of these tumors, physical therapy plays an important role in maintaining muscle strength, range of motion, and preventing contractures after surgical and IR procedures. Surgical excision has a limited, if any, role in the management of these patients.
10
In conclusion, FFVA in PHTS present with recurrent pain requiring life-long management with a multi-disciplinary team. Pain due to FFVA responds to embolization, and that due to PTEN hamartoma of soft tissue responds to sirolimus.
Long-term combined use of IR procedures and medical therapy can improve the quality of life, but does not prevent disease progression. A comprehensive evaluation of the PHTS patient, identification of pain triggers, and targeting of all elements contributing to the symptoms are essential for success of therapy.
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